First pick: ACDC
ACDC is a high-CBD cultivar. Published lab panels put CBD between 16% and 20% and THC below 1%. THC is the molecule that causes intoxication. A ratio near 20:1 lets a patient take a dose in the daytime and stay clear.
One caution. No strain treats cancer. The National Cancer Institute states that cannabinoids have been studied for symptom control, and that no human trial shows cannabis cures cancer. The FDA has approved three cannabinoid drugs: dronabinol (1985), nabilone (1985), and cannabidiol (2018). The first two treat chemotherapy-induced nausea and vomiting. The third treats two rare seizure disorders, not cancer.
ACDC holds value for symptoms patients report: less nausea, more appetite, less pain. The evidence base for flower is thin. The evidence base for the drug forms is not.
cannabis oil for cancer patients chemotherapy
Options
Harlequin
CBD to THC near 5:2. Lab panels list 8% to 10% CBD and 4% to 5% THC. Mild psychoactivity. Patients who want some THC and some CBD pick this one.
Cannatonic
Ratio runs from 1:1 to 2:1. THC 4% to 8%, CBD 6% to 12%. Batch to batch spread is wide. Ask for the panel for the lot in your hand.
Northern Lights
Indica. THC 16% to 21%, CBD under 1%. Used at night for sleep and appetite. High THC raises the risk of dizziness and anxiety in new users.
Charlotte's Web
CBD up to 20%, THC under 0.3%. Sold as hemp in states with no medical program. Dose control is the weak point. Hemp oil sits outside state lab rules in some markets.
Convenience is now the deciding factor
Flower needs a grinder, a lighter, and a room with air. A capsule needs water. An oil needs a dropper and a number: 10 mg per 0.5 ml.
For a patient on a chemotherapy schedule, dose per unit decides the purchase. Dispensary menus show this. Vape carts, tinctures, capsules, and pre-rolls sit above loose flower in most storefronts.
Two checks before buying. First, ask for the certificate of analysis and match the batch number to the package. Second, read the CBD to THC ratio on that panel, not on the label. Labels drift between harvests.
Unknown: long-term outcomes for strain-specific use in oncology. No registry tracks it at scale, and strain names repeat across unrelated genetics.